Odyssey Therapeutics, Inc. (ODTX)
$24.27-$1.62 (-6.24%) Today
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.
No Form 4 activity for ODTX in the last 90 days.
15 Form 4 filings on record, the earliest from May 12, 2026, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| TPG GP A, LLC | Other | Common Stock | 423,111 | - | - | |
| TPG GP A, LLC | Other | Common Stock | 2,351 | $18.00 | $42K | |
| TPG GP A, LLC | Other | Common Stock | 1,880,497 | - | - | |
| TPG GP A, LLC | Open-market purchase | Common Stock | 1,388,889 | $18.00 | $25.00M | |
| TPG GP A, LLC | Other | Warrants (right to buy) | 423,111 | - | - | |
| TPG GP A, LLC | Other | Series D Preferred Stock | 18,272,789 | - | - | |
| Dimension Capital II, L.P. - Director | Other | Common Stock | 1,709,543 | - | - | |
| Dimension Capital II, L.P. - Director | Open-market purchase | Common Stock | 1,111,111 | $18.00 | $20.00M | |
| Dimension Capital II, L.P. - Director | Other | Series D Convertible Preferred Stock | 16,611,626 | - | - | |
| SR ONE CAPITAL MANAGEMENT, LLC | Other | Common Stock | 474,048 | - | - | |
| SR ONE CAPITAL MANAGEMENT, LLC | Other | Common Stock | 139,366 | - | - | |
| SR ONE CAPITAL MANAGEMENT, LLC | Other | Common Stock | 59,692 | - | - | |
| SR ONE CAPITAL MANAGEMENT, LLC | Other | Common Stock | 61,762 | - | - | |
| SR ONE CAPITAL MANAGEMENT, LLC | Other | Common Stock | 683,817 | - | - | |
| SR ONE CAPITAL MANAGEMENT, LLC | Other | Common Stock | 191,541 | - | - | |
| SR ONE CAPITAL MANAGEMENT, LLC | Open-market sale | Common Stock | 1,065 | $18.00 | $19K | |
| SR ONE CAPITAL MANAGEMENT, LLC | Open-market purchase | Common Stock | 222,222 | $18.00 | $4.00M | |
| SR ONE CAPITAL MANAGEMENT, LLC | Other | Common Stock | 118,512 | - | - | |
| SR ONE CAPITAL MANAGEMENT, LLC | Other | Common Stock | 255,823 | - | - | |
| SR ONE CAPITAL MANAGEMENT, LLC | Other | Common Stock | 204,658 | - | - | |
| SR ONE CAPITAL MANAGEMENT, LLC | Other | Common Stock | 20,582 | - | - | |
| SR ONE CAPITAL MANAGEMENT, LLC | Other | Common Stock | 166,168 | - | - | |
| SR ONE CAPITAL MANAGEMENT, LLC | Other | Common Stock | 49,850 | - | - | |
| SR ONE CAPITAL MANAGEMENT, LLC | Open-market sale | Common Stock | 277 | $18.00 | $5K | |
| SR ONE CAPITAL MANAGEMENT, LLC | Open-market purchase | Common Stock | 133,333 | $18.00 | $2.40M | |
| SR ONE CAPITAL MANAGEMENT, LLC | Other | Common Stock | 463,106 | - | - | |
| SR ONE CAPITAL MANAGEMENT, LLC | Other | Common Stock | 273,527 | - | - | |
| SR ONE CAPITAL MANAGEMENT, LLC | Other | Common Stock | 78,656 | - | - | |
| SR ONE CAPITAL MANAGEMENT, LLC | Open-market sale | Common Stock | 438 | $18.00 | $8K | |
| SR ONE CAPITAL MANAGEMENT, LLC | Open-market purchase | Common Stock | 200,000 | $18.00 | $3.60M | |
| SR ONE CAPITAL MANAGEMENT, LLC | Other | Series A Convertible Preferred Stock | 4,606,320 | - | - | |
| SR ONE CAPITAL MANAGEMENT, LLC | Other | Series A-2 Convertible Preferred Stock | 1,299,842 | - | - | |
| SR ONE CAPITAL MANAGEMENT, LLC | Other | Series B Convertible Preferred Stock | 544,162 | - | - | |
| SR ONE CAPITAL MANAGEMENT, LLC | Other | Series C Convertible Preferred Stock | 600,142 | - | - | |
| SR ONE CAPITAL MANAGEMENT, LLC | Other | Series D Convertible Preferred Stock | 6,644,650 | - | - | |
| SR ONE CAPITAL MANAGEMENT, LLC | Other | Series D Warrants (Right to Buy) | 1,861,211 | - | - | |
| SR ONE CAPITAL MANAGEMENT, LLC | Other | Series A Convertible Preferred Stock | 1,151,580 | - | - | |
| SR ONE CAPITAL MANAGEMENT, LLC | Other | Series B Convertible Preferred Stock | 2,374,981 | - | - | |
| SR ONE CAPITAL MANAGEMENT, LLC | Other | Series B Convertible Preferred Stock | 1,899,984 | - | - | |
| SR ONE CAPITAL MANAGEMENT, LLC | Other | Series C Convertible Preferred Stock | 200,000 | - | - | |
| SR ONE CAPITAL MANAGEMENT, LLC | Other | Series D Convertible Preferred Stock | 1,614,650 | - | - | |
| SR ONE CAPITAL MANAGEMENT, LLC | Other | Series D Warrants (Right to Buy) | 484,395 | - | - | |
| SR ONE CAPITAL MANAGEMENT, LLC | Other | Series C Convertible Preferred Stock | 4,500,000 | - | - | |
| SR ONE CAPITAL MANAGEMENT, LLC | Other | Series D Convertible Preferred Stock | 2,657,860 | - | - | |
| SR ONE CAPITAL MANAGEMENT, LLC | Other | Series D Warrants (Right to Buy) | 764,312 | $0.00 | - | |
| Jeffrey M. Leiden | Open-market purchase | Common Stock | 5,000 | $20.00 | $100K | |
| Jeffrey M. Leiden | Other | Common Stock | 28,698 | - | - | |
| Jeffrey M. Leiden | Option exercise | Common Stock | 2,963 | - | - | |
| Jeffrey M. Leiden | Tax withholding / forfeiture | Common Stock | 17 | $18.00 | $306 | |
| Jeffrey M. Leiden | Other | Series B Convertible Preferred Stock | 79,166 | - | - | |
| Jeffrey M. Leiden | Other | Series C Convertible Preferred Stock | 100,000 | - | - | |
| Jeffrey M. Leiden | Grant or award | Stock Option (Right to Buy) | 626,220 | $0.00 | - | |
| Jeffrey M. Leiden | Other | Series D Convertible Preferred Stock | 96,002 | - | - | |
| Jeffrey M. Leiden | Option exercise | Series D Warrants (Right to Buy) | 28,800 | - | - | |
| Jason Haas - Officer | Open-market purchase | Common Stock | 1,000 | $20.00 | $20K | |
| Nan (Ln) Li | Other | Common Stock | 1,709,543 | - | - | |
| Nan (Ln) Li | Open-market purchase | Common Stock | 1,111,111 | $18.00 | $20.00M | |
| Nan (Ln) Li | Other | Series D Convertible Preferred Stock | 16,611,626 | - | - | |
 Ian F. Smith | Grant or award | Stock Option (Right to Buy) | 27,393 | $0.00 | - | |
| Valerie Odegard | Grant or award | Stock Option (Right to Buy) | 27,393 | $0.00 | - | |
| Shelley Chu | Open-market purchase | Common Stock | 11,111 | $18.00 | $200K | |
| Ourania Tatsis | Grant or award | Stock Option (Right to Buy) | 27,393 | $0.00 | - | |
| Natalie Dales - Officer | Grant or award | Stock Option (Right to Buy) | 79,773 | $0.00 | - | |
 Timothy P. Walbert | Grant or award | Stock Option (Right to Buy) | 27,393 | $0.00 | - | |
 Gary D. Glick - Officer | Grant or award | Stock Option (Right to Buy) | 884,450 | $0.00 | - | |
| Gary D. Glick - Officer | Other | Common Stock | 27,386 | - | - | |
| Gary D. Glick - Officer | Other | Series C Convertible Preferred Stock | 100,000 | - | - | |
| Gary D. Glick - Officer | Other | Series D Convertible Preferred Stock | 166,116 | - | - | |
| Anthony W. Opipari - Officer | Option exercise | Common Stock | 541 | - | - | |
| Anthony W. Opipari - Officer | Other | Common Stock | 6,965 | - | - | |
| Anthony W. Opipari - Officer | Tax withholding / forfeiture | Common Stock | 4 | $18.00 | $72 | |
| Anthony W. Opipari - Officer | Other | Series A Convertible Preferred Stock | 18,531 | - | - | |
| Anthony W. Opipari - Officer | Other | Series B Convertible Preferred Stock | 11,083 | - | - | |
| Anthony W. Opipari - Officer | Other | Series C Convertible Preferred Stock | 20,000 | - | - | |
| Anthony W. Opipari - Officer | Other | Series D Convertible Preferred Stock | 17,545 | - | - | |
| Anthony W. Opipari - Officer | Grant or award | Stock Option (Right to Buy) | 250,203 | $0.00 | - | |
| Anthony W. Opipari - Officer | Grant or award | Stock Option (Right to Buy) | 27,777 | $0.00 | - | |
| Anthony W. Opipari - Officer | Option exercise | Series D Warrants (Right to Buy) | 5,263 | - | - | |
| Collin M. Todd - Officer | Grant or award | Stock Option (Right to Buy) | 93,904 | $0.00 | - |
Odyssey Therapeutics, Inc. (ODTX) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-05-13. The full record for ODTX runs to 15 Form 4 filings, the earliest from 2026-05-12. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of ODTX were filed in the last 90 days. 9 purchases are on record for this company.
No insider sales of ODTX were filed in the last 90 days. 3 sales are on record for this company.
This page tracks ODTX Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add ODTX to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
